Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 02, 2023

SELL
$6.7 - $24.21 $5,561 - $20,094
-830 Reduced 8.79%
8,611 $208,000
Q4 2022

Feb 10, 2023

BUY
$4.52 - $10.57 $2,024 - $4,735
448 Added 4.98%
9,441 $100,000
Q3 2022

Nov 09, 2022

BUY
$3.43 - $5.62 $1,444 - $2,366
421 Added 4.91%
8,993 $40,000
Q2 2022

Aug 15, 2022

BUY
$3.65 - $7.3 $6,810 - $13,621
1,866 Added 27.83%
8,572 $34,000
Q1 2022

Jun 30, 2022

BUY
$3.4 - $7.88 $22,800 - $52,843
6,706 New
6,706 $49,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.